1
|
A Novel Reduced Graphene Oxide Modified Carbon Paste Electrode for Potentiometric Determination of Trihexyphenidyl Hydrochloride in Pharmaceutical and Biological Matrices. SENSORS 2021; 21:s21092955. [PMID: 33922519 PMCID: PMC8122888 DOI: 10.3390/s21092955] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 04/16/2021] [Accepted: 04/19/2021] [Indexed: 12/02/2022]
Abstract
A novel promising carbon paste electrode with excellent potentiometric properties was prepared for the analysis of trihexyphenidyl hydrochloride (THP), the acetylcholine receptor and an anticholinergic drug in real samples. It contains 10.2% trihexyphenidy-tetraphenylborate ionic pair as the electroactive material, with the addition of 3.9% reduced graphene oxide and 0.3% of anionic additive into the paste, which consists of 45.0% dibutylphthalate as the solvent mediator and 40.6% graphite. Under the optimized experimental conditions, the electrode showed a Nernstian slope of 58.9 ± 0.2 mV/decade with a regression coefficient of 0.9992. It exhibited high selectivity and reproducibility as well as a fast and linear dynamic response range from 4.0 × 10−7 to 1.0 × 10−2 M. The electrode remained usable for up to 19 days. Analytical applications showed excellent recoveries ranging from 96.8 to 101.7%, LOD was 2.5 × 10−7 M. The electrode was successfully used for THP analysis of pharmaceutical and biological samples.
Collapse
|
2
|
Lu C, Fu K, Cao K, Wei J, Zhou J, Zhao D, Li N, Lu Y, Chen X, Zhang Y. Permeability and transport mechanism of trihexyphenidyl hydrochloride in Caco-2 cell monolayer model with a validated UPLC-MS/MS method. J Pharm Biomed Anal 2020; 178:112924. [DOI: 10.1016/j.jpba.2019.112924] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 09/02/2019] [Accepted: 10/10/2019] [Indexed: 12/30/2022]
|
3
|
Chen X, Zhang J, Li Y, Han S. Chemiluminescence of copper nanoclusters and its application for trihexyphenidyl hydrochloride detection. LUMINESCENCE 2018; 33:962-967. [DOI: 10.1002/bio.3496] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 03/28/2018] [Accepted: 04/07/2018] [Indexed: 11/12/2022]
Affiliation(s)
- Xiaoxia Chen
- School of Chemistry and Material Science; Shanxi Normal University; Linfen Shanxi P. R. China
| | - Junmei Zhang
- School of Chemistry and Material Science; Shanxi Normal University; Linfen Shanxi P. R. China
| | - Yue Li
- School of Chemistry and Material Science; Shanxi Normal University; Linfen Shanxi P. R. China
| | - Suqin Han
- School of Chemistry and Material Science; Shanxi Normal University; Linfen Shanxi P. R. China
- Department of Chemistry; Modern College of Humanities and Sciences of Shanxi Normal University; Linfen Shanxi P. R. China
| |
Collapse
|
4
|
Agúndez JAG, García-Martín E, Alonso-Navarro H, Jiménez-Jiménez FJ. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 2013; 9:859-74. [PMID: 23565891 DOI: 10.1517/17425255.2013.789018] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
INTRODUCTION The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers. These biomarkers are then used as surrogate endpoints. This review analyzes potential genetic biomarkers which can be used to improve anti-Parkinson's disease therapy. AREAS COVERED The authors present an overview of current knowledge of pharmacogenetic implications of anti-Parkinson's disease drugs, including genes coding for the corresponding drug-metabolizing enzymes and drug targets. The gene/drug pairings with the strongest potential for pharmacogenetic recommendations include: CYP2C19/benztropine, COMT/levodopa and entacapone, CYP2B6/selegiline, UGT1A/entacapone, DRD2/ropinirole, pramipexole and cabergoline, and DRD3/ropinirole and pramipexole. Evidence supporting the effect of substrates, inhibitor or inducers for drug specific metabolizing enzymes in anti-Parkinson's disease drug response includes CYP1A2 in the response to ropinirole and rasagiline, and CYP3A4 in the response to bromocriptine, lisuride, pergolide and cabergoline. The authors present and discuss the current information on gene variations according to the 1000 genomes catalog and other databases with regards to anti-Parkinson's disease drugs. They also review and discuss the clinical implications of these variations. EXPERT OPINION The goal of pharmacogenomic testing for anti-Parkinson's disease drugs should be conservative and aimed at selecting determined drugs for determined patients. However, much additional research is still needed to obtain reliable pre-prescription tests.
Collapse
Affiliation(s)
- José A G Agúndez
- University of Extremadura, Department of Pharmacology, Avda. de la Universidad s/n, E-10071, Cáceres, Spain.
| | | | | | | |
Collapse
|
5
|
Chu BL, Feng Q, Wang Z, Lin JM. Enantiomeric Separation of Two Antiparkinsonian Drugs by Electrokinetic Chromatography Using Dextran Sulfate. Chromatographia 2009. [DOI: 10.1365/s10337-009-1232-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Zhang J, Li J, Tu Y. Flow injection determination of benzhexol based on its sensitizing effect on the chemiluminescent reaction of Ce(IV)-sulfite. LUMINESCENCE 2009; 25:317-21. [PMID: 19630094 DOI: 10.1002/bio.1154] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In this paper, a novel chemiluminescent (CL) method for the determination of benzhexol has been developed by combining the flow injection technique and its sensitizing effect on the weak CL reaction between sulfite and acidic cerium(IV). A mechanism for the CL reaction has been proposed on the basis of CL spectra. Under the optimized conditions, the proposed method allows the measurement of benzhexol hydrochloride over the range 0.1-10 microg/mL with a correlation coefficient of 0.9992 (n = 8), a detection limit of 0.02 microg/mL (3sigma), and a relative standard deviation for 2.0 microg/mL benzhexol (n = 11) of 1.65%. The utility of this method was demonstrated by determining benzhexol hydrochloride in tablets.
Collapse
Affiliation(s)
- Jingkai Zhang
- College of Chemistry, Chemical Engineering and materials science, Soochow University, Suzhou 215123, People's Republic of China
| | | | | |
Collapse
|
7
|
Steroselective determination of trihexyphenidyl using carboxylmethyl-β-cyclodextrin by capillary electrophoresis with field-amplified sample stacking. Microchem J 2008. [DOI: 10.1016/j.microc.2007.11.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
8
|
Merino F, Rubio S, Pérez-Bendito D. Supramolecular systems-based extraction-separation techniques coupled to mass spectrometry. J Sep Sci 2006; 28:1613-27. [PMID: 16224955 DOI: 10.1002/jssc.200500161] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The combination of supramolecular chemistry and MS has not only been fruitful in the field of gas-phase fundamental studies of host-guest complexes and supramolecular assemblies. Mass spectrometric analysis has also benefited from the ability of supramolecular systems to behave as pseudophases in which solutes partition from the bulk solvent phase. Supramolecular systems-based extraction and concentration schemes and separation techniques have been widely used in different fields of analytical chemistry and are ideally suited for coupling with MS. This review describes the present status of the application of supramolecular chemistry in mass spectrometric analysis and includes topics such as the use of coacervative liquid-liquid extraction and hemimicelle/admicelle-based SPE of organic compounds prior to chromatography and electrophoresis. It also discusses the recent advances in enantioselective analysis using CD in electrophoresis- and chromatography-MS. The potential and analytical challenges of these approaches in environmental and bioanalytical chemistry, where one can expect significant developments in the future, are outlined.
Collapse
Affiliation(s)
- Francisco Merino
- Department of Analytical Chemistry, Campus de Rabanales, Edificio Anexo Marie Curie, University of Córdoba, Córdoba, Spain
| | | | | |
Collapse
|
9
|
Yan J, Liu J, Cao W, Sun X, Yang X, Wang E. Determination of benzhexol hydrochloride by capillary zone electrophoresis with an end-column electrochemiluminescence detection. Microchem J 2004. [DOI: 10.1016/j.microc.2003.10.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41:261-309. [PMID: 11978145 DOI: 10.2165/00003088-200241040-00003] [Citation(s) in RCA: 210] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Current research in Parkinson's disease (PD) focuses on symptomatic therapy and neuroprotective interventions. Drugs that have been used for symptomatic therapy are levodopa, usually combined with a peripheral decarboxylase inhibitor, synthetic dopamine receptor agonists, centrally-acting antimuscarinic drugs, amantadine, monoamine oxidase-B (MAO-B) inhibitors and catechol-O-methyltransferase (COMT) inhibitors. Drugs for which there is at least some evidence for neuroprotective effect are certain dopamine agonists, amantadine and MAO-B inhibitors (selegiline). Levodopa remains the most effective drug for the treatment of PD. Several factors contribute to the complex clinical pharmacokinetics of levodopa: erratic absorption, short half-life, peripheral O-methylation and facilitated transport across the blood-brain barrier. In patients with response fluctuations to levodopa, the concentration-effect curve becomes steeper and shifts to the right compared with patients with stable response. Pharmacokinetic-pharmacodynamic modelling can affect decisions regarding therapeutic strategies. The dopamine agonists include ergot derivatives (bromocriptine, pergolide, lisuride and cabergoline), non-ergoline derivatives (pramipexole, ropinirole and piribedil) and apomorphine. Most dopamine agonists have their specific pharmacological profile. They are used in monotherapy and as an adjunct to levodopa in early and advanced PD. Few pharmacokinetic and pharmacodynamic data are available regarding centrally acting antimuscarinic drugs. They are characterised by rapid absorption after oral intake, large volume of distribution and low clearance relative to hepatic blood flow, with extensive metabolism. The mechanism of action of amantadine remains elusive. It is well absorbed and widely distributed. Since elimination is primarily by renal clearance, accumulation of the drug can occur in patients with renal dysfunction and dosage reduction must be envisaged. The COMT inhibitors entacapone and tolcapone dose-dependently inhibit the formation of the major metabolite of levodopa, 3-O-methyldopa, and improve the bioavailability and reduce the clearance of levodopa without significantly affecting its absorption. They are useful adjuncts to levodopa in patients with end-of-dose fluctuations. The MAO-B inhibitor selegiline may have a dual effect: reducing the catabolism of dopamine and limiting the formation of neurotoxic free radicals. The pharmacokinetics of selegiline are highly variable; it has low bioavailability and large volume of distribution. The oral clearance is many-fold higher than the hepatic blood flow and the drug is extensively metabolised into several metabolites, some of them being active. Despite the introduction of several new drugs to the antiparkinsonian armamentarium, no single best treatment exists for an individual patient with PD. Particularly in the advanced stage of the disease, treatment should be individually tailored.
Collapse
Affiliation(s)
- Dirk Deleu
- College of Medicine, Sultan Qaboos University, PO Box 35, Al Khod, Sultanate of Oman.
| | | | | |
Collapse
|
11
|
Cápka V, Xu Y. Simultaneous determination of enantiomers of structurally related anticholinergic analogs in human serum by liquid chromatography-electrospray ionization mass spectrometry with on-line sample cleanup. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 762:181-92. [PMID: 11678378 DOI: 10.1016/s0378-4347(01)00364-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Trihexyphenidyl, biperiden and procyclidine are anticholinergic drugs produced as racemates for the treatment of Parkinson's disease. This paper describes a simple and sensitive LC-MS method for the simultaneous determination of these compounds in human serum. An on-line sample clean-up procedure was used, where serum samples were directly injected into a "restricted-access media" pre-column. After the exclusion of the serum proteins, the drug molecules were eluted to a beta-cyclodextrin analytical column for chiral separation. The quantitation was done by electrospray ionization MS using diphenidol as an internal standard. The method developed has limits of detection of 1 ng/ml, at least two-orders-of-magnitude linear dynamic ranges (r>0.999), and RSDs of less than 10%. The system can be completely automated for increased sample throughput and unattended analyses.
Collapse
Affiliation(s)
- V Cápka
- Department of Chemistry, Cleveland State University, OH 44115, USA
| | | |
Collapse
|
12
|
Abstract
Recent advances in mass spectrometry have rendered it an attractive and versatile tool in industrial and academic research laboratories. As a part of this rapid growth, a considerable body of literature has been devoted to the application of mass spectrometry in studies involving enantioselectivity, molecular recognition, and supramolecular chemistry. In concert with separation techniques such as capillary electrophoresis and liquid chromatography, mass spectrometry allows rapid characterization of a large array of molecules in complex mixtures. A majority of these findings have been made possible by the introduction of 'soft-ionization' techniques such as electrospray ionization interface. Other techniques such as atmospheric pressure chemical ionization mass spectrometry have been widely used as a rugged interface for quantitative liquid chromatography-mass spectrometry. Herein, we present a brief overview of the above techniques accompanied with several examples of enantioselective capillary electrophoresis- and liquid chromatography-mass spectrometry in drug discovery and development. Although the emphasis of this article is on quantitative enantiomeric chromatography-mass spectrometry, we envisage that similar strategies are adaptable in qualitative studies.
Collapse
Affiliation(s)
- R Bakhtiar
- Department of Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research, East Hanover, New Jersey, USA.
| | | | | |
Collapse
|
13
|
Bakhtiar R, Tse FL. High-throughput chiral liquid chromatography/tandem mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2000; 14:1128-1135. [PMID: 10867688 DOI: 10.1002/1097-0231(20000715)14:13<1128::aid-rcm1>3.0.co;2-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Chiral liquid chromatography is a well-established area of bioanalytical chemistry and is often used during the processes of drug discovery and development. The development and use of a chiral drug require the understanding of the pharmacokinetic characteristics of each of the enantiomers, including potential differences in their absorption, distribution, metabolism, and excretion. Chromatographic techniques coupled to atmospheric pressure ionization-tandem mass spectrometry have shown potential as sensitive and robust tools in the quantitative and qualitative determination of enantiomers in biologic fluids and tissue extracts. However, development of a chiral liquid chromatography method requires time-consuming procedures that are devised empirically. Clearly, there is an incentive to design chromatographic approaches that are easy to use, compatible with mass spectrometry ionization interface conditions, exhibit relatively short run times without compromising sensitivity, and offer a broad analyte specificity. For these reasons, the present paper explores the feasibility of the bonded macrocyclic glycopeptide phases (teicoplanin and vancomycin) for analysis by chiral liquid chromatography/tandem mass spectrometry. Ritalinic acid, pindolol, fluoxetine, oxazepam, propranolol, terbutaline, metoprolol, and nicardipine were tested in this study. Furthermore, an example of a simultaneous chiral LC/MS/MS detection (chromatographic run time approximately 10 min) of four pharmaceutical products resulting in baseline resolutions of all four pairs of enantiomers is presented. Methanol, an MS-compatible mobile phase, was utilized in all the experiments.
Collapse
Affiliation(s)
- R Bakhtiar
- Department of Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research, East Hanover, NJ 07936, USA.
| | | |
Collapse
|